Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA OK's Gilead's 'TAF' Combo HIV Drug Odefsey

This article was originally published in Scrip

Executive Summary

Gilead Sciences Inc. on March 1 gained the FDA's approval to market Odefsey as a treatment for HIV-1 infection – the second so-called TAF-based regimen to win the agency's OK.


Related Content

Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
2Q Pharma Results Preview: What Lies Ahead
Gilead Gets CHMP Nod for New HIV Combo





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts